CTMX earnings date and last-quarter result: next report 2026-08-06, last quarter beat, P/E -9.22. Updated 2026-07-23.
CytomX Therapeutics (CTMX) Research Hub
CytomX Therapeutics (CTMX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.23 USD (-3.88%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -9.22, market cap 0.54B. This hub links to the full technical, earnings and options research available for CTMX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.23 USD (-3.88%) |
| 52-week range | 2.18 USD – 3.96 USD |
| Trend regime | Range |
| 14-day RSI | 38.5 (Bearish) |
| Trailing P/E | -9.22 |
| Market cap | 0.54B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for CTMX
Covered Call on CTMX: how it works, illustrative setup around the real 2.23 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CTMX: how it works, illustrative setup around the real 2.23 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CTMX: how it works, illustrative setup around the real 2.23 USD price, max profit/loss, breakeven and when to use it. Educational.
CTMX technical analysis: range, last 2.23 USD, RSI 38.5, 52w range 2.18 USD–3.96 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CTMX in?
CytomX Therapeutics (CTMX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CTMX in an uptrend or downtrend?
As of 2026-10-26, CTMX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CTMX's trailing P/E ratio?
CTMX's trailing P/E is -9.22, with a market cap of 0.54B. See the earnings research page for full valuation detail.
When does CTMX next report earnings?
CTMX is next scheduled to report earnings on 2026-08-06.